Novo Nordisk Finally Got the Win It Needed: Phase 2 Amycretin Results

Original posted at obesity.news/ on Nov 25, 2025

Novo Nordisk needed some good news desperately, and today they got it. After a string of trial setbacks, pulled programs, and rising pressure to prove they can still lead the next era of metabolic medicine, the company finally dropped some extremely positive news. Amycretin, their GLP-1 and amylin combo drug, posted phase two results in people with type two diabetes that are not just strong, they are the game changers for type 2 diabetes.

And for our community, for the people waking up every day trying to keep blood sugar stable, trying to lose weight against biology that keeps dragging them backward, trying to get a doctor to finally take them seriously, this is more than corporate good news. This is the kind of data that can the change entire trajectory their lives.

A New Chapter For Amycretin Begins

Novo Nordisk just completed the first ever phase 2 trial of amycretin in people with type 2 diabetes. These were adults already taking metformin, and many were also on an SGLT2 inhibitor. The trial included 448 people, and it tested both weekly injections and daily oral doses for 36 weeks.

Amycretin is a single molecule that activates the GLP-1 receptor and the amylin receptor. Bringing those two pathways together has been the dream for years because amylin is one of the earliest hormones to crash in diabetes and obesity. When you restore it alongside GLP-1, you get better appetite control, better satiety, and tighter blood sugar regulation.

This is why everyone has been watching this drug so closely.

A1c Improvements

At the start, participants had A1c levels around 7.8 or 8.0. By week 36, the amycretin groups saw:

• Up to 1.8% A1c reduction with weekly injections

• Up to 1.5% with daily oral dosing

• Up to 89% achieved an A1c under seven

• Up to 76% reached 6.5 or lower

Unsurprisingly, placebo barely moved.

These are excellent improvements in A1c, but still fall quite short of tirzeaptide’s numbers from surpass.

The weight loss is what will get people talking

From a baseline around 100kg:

• Weekly amycretin delivered up to 14.5% weight loss

• Oral amycretin delivered up to 10%

• Placebo sat around 2-3%

• There was no plateau at week 36

That last point matters. When a curve has not flattened by week 36, it usually means the drug is still building momentum. It means the ceiling is higher than what we saw today.

And when you stack those numbers against tirzepatide at a similar point in time, things get even more interesting. In the SURPASS trials, the 15mg dose of tirzepatide delivered roughly 12-14% weight loss by week 36 to week 40, depending on the study and the baseline weight of the population. Amycretin is already sitting at 15.5% at week 36, and it reached that number after spending only 4 weeks at its top dose. Tirzepatide had a longer runway, meaning that in order to achieve these results, patients were on the highest dose for nearly 20 weeks. In other words, Amycretin still has a good bit of gas in the tank at the highest dose. When a first time molecule can match the reigning champion before the curve even levels out, that tells you the ceiling here is not just high, it is still hidden.

Safety Profile Looks Like What We Already Know

The side effects were mainly gastrointestinal and were mostly mild to moderate. No new safety issues. Nothing unexpected. Nothing that would make clinicians or patients pause.

That is a big deal for a drug combining two powerful hormonal pathways in one molecule.

Why This Matters Right Now

People with type 2 diabetes are exhausted. They have carried the weight of misinformation, shame, and dismissal for decades. They have been offered diet sheets instead of real treatment. They have been told that if they just tried harder they would get better.

And now, one by one, the science keeps proving what patients have been saying all along. This is biology, not willpower. And biology can be treated.

Amycretin is not a miracle. It is not here tomorrow. It still has a full phase 3 program ahead of

it.

But today was good news, and Novo (and I) needed it!

This article is reader-supported on Substack.

To receive new posts and support my work,

consider becoming a free or paid subscriber.

Subscribe